BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) (www.regenerx.com) today reported on the results of several important research programs with Thymosin beta 4 (Tß4) presented at the Second International Symposium on Thymosins in Health and Disease, in Catania, Italy. The following are synopses of the presentations:
